Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide chemoradiotherapy for pediatric high-grade glioma, pontine glioma, or gliomatosis cerebri
ISRCTN19852453Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Jun 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in glioma, diffuse intrinsic pontine glioma (DIPG) and gliomatosis cerebri (GC), sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: Event status at 6 months after diagnosis. Started Jun 2009; status: completed.
02
Drugs
temozolomide
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)gliomatosis cerebri (GC)
Beyond the preview
Go deeper on ISRCTN19852453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN19852453.